NCT03267433 2026-03-02
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
Clinical Trials
14 trialsNCT04870944 2026-02-24
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
Phase 1/2 Recruiting
NCT07144826 2026-02-13
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05847569 2026-02-03
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Recruiting
NCT04659616 2025-12-19
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
OHSU Knight Cancer Institute
Phase 1 Recruiting
NCT06672224 2025-09-17
Indocyanine Green Fluoroscopy and SPY Angiography for the Assessment of Lymphatic Structure in Breast Cancer Patients at Risk for Breast Cancer-Related Lymphedema
City of Hope Medical Center
Phase NA Withdrawn
NCT07174128 2025-09-15
Two Cut-Off Values of Plethysmographic Variability Index to Guide Intraoperative Fluid Therapy on Serum Lactate in Patients Undergoing Excision of Supra-Tentorial Brain Tumors
Cairo University
Phase NA Completed
NCT03941860 2025-05-23
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
National Cancer Institute (NCI)
Phase 3 Completed
NCT04987463 2024-02-08
ViRap
Children's Memorial Health Institute, Poland
Phase 2/3 Recruiting
NCT02257567 2022-11-14
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT03062059 2022-04-14
The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence
National Cancer Center, Korea
Phase 2 Unknown
NCT02100969 2021-06-02
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
University of Kansas Medical Center
Phase 2 Completed
NCT01132755 2019-06-14
Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00667485 2014-01-17
Rapamycin Plus Bevacizumab in Advanced Cancers
University of Chicago
Phase 1 Completed